Characteristics | OrM3 | Placebo | Ipratropium |
4 mg | 3 mg | 2 mg | 0.5 mg | | |
Subjects n | 67 | 69 | 73 | 72 | 68 | 63 |
Age yrs | 67 (46–86) | 65 (46–81) | 67 (43–81) | 66 (37–83) | 64 (43–80) | 66 (39–85) |
Male | 52 | 50 | 60 | 51 | 57 | 60 |
Ethnic origin | | | | | | |
White | 94 | 87 | 95 | 99 | 93 | 96 |
Black | 3 | 9 | 4 | 1 | 7 | 2 |
Other | 3 | 4 | 1 | 0 | 0 | 2 |
Duration of COPD yrs | 6.9±5.8 | 7.5±7.2 | 6.5±5.6 | 7.1±6.8 | 5.9±5.1 | 6.7±6.3 |
Smoking history pack-yrs | 63.9±31.6 | 62.9±41.2 | 60.5±30.5 | 59.3±38.9 | 63.8±40.6 | 56.2±27.5 |
FEV1 L | 1.1±0.5 | 1.1±0.4 | 1.2±0.5 | 1.3±0.5 | 1.2±0.5 | 1.4±0.6 |
FEV1 % pred | 40.2±15.8 | 37.8±12.9 | 38.9±13.4 | 44.2±13.4 | 40.4±14.4 | 43.3±15.2 |
FEV1 % pred ipratropium reversibility | 23.3±15.6 | 21.2±10.5 | 22.0±12.9 | 20.2±15.2 | 20.0±11.5 | 21.3±10.1 |
FEV1/FVC | 51±17 | 50±17 | 51±17 | 53±17 | 53±22 | 52±16 |
Morning PEFR L·min-1 | 250.7±86.7 | 231.3±71.9 | 263.4±97.8 | 276.4±56.2 | 254.3±85.9 | 273.3±105.6 |
Evening PEFR L·min-1 | 241.6±84.6 | 217.4±73.7 | 254.4±96.6 | 260.1±86.0 | 244.4±91.5 | 260.3±104.7 |
β-agonist use puffs·day-1 | 5.1±4.0 | 5.5±3.8 | 5.4±4.3 | 4.6±3.5 | 5.3±3.4 | 5.3±4.4 |
MRC score | 3.3±0.9 | 3.3±0.8 | 3.0±0.9 | 3.0±0.9 | 2.9±0.9 | 2.9±1.0 |
BDI focal score | 5.6±2.1 | 5.3±1.6 | 5.6±1.9 | 5.8±1.9 | 5.7±2.1 | 5.2±2.0 |
CRQ average of 4 domains | 4.3±0.9 | 4.1±0.8 | 4.4±0.9 | 4.3±0.9 | 4.3±1.0 | 4.2±1.0 |
Daytime overall COPD symptoms score | 2.1±0.8 | 2.2±0.8 | 2.0±0.8 | 2.1±0.8 | 2.1±0.8 | 2.2±0.9 |
Night-time awakenings | 0.6±0.5 | 0.5±0.4 | 0.7±0.7 | 0.6±0.5 | 0.6±0.6 | 0.9±0.7 |